Signatera™ for early detection of molecular residual disease using ctDNA
Detect residual disease and recurrence early in colorectal cancer (CRC). How often should Signatera be ordered for CRC patients?
Read More
Detect residual disease and recurrence early in colorectal cancer (CRC). How often should Signatera be ordered for CRC patients?
Read More
The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions. Read our billing guide for information about understanding Natera's genetic testing bill.
Read More